PT - JOURNAL ARTICLE AU - Florentino Carral San Laureano AU - Mariana Tomé Fernández-Ladreda AU - Ana Isabel Jiménez Millán AU - Concepción García Calzado AU - María del Carmen Ayala Ortega TI - Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice AID - 10.1136/jim-2020-001633 DP - 2021 Jun 01 TA - Journal of Investigative Medicine PG - 983--988 VI - 69 IP - 5 4099 - http://hw-f5-jim.highwire.org/content/69/5/983.short 4100 - http://hw-f5-jim.highwire.org/content/69/5/983.full SO - J Investig Med2021 Jun 01; 69 AB - There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.All data relevant to the study are included in the article or uploaded as supplementary information.